{"component": "definition", "props": {"groups": [{"size": 6, "samples": [{"hash": "6UWc4iKpUEd", "uri": "https://www.legislation.gov.uk/nisr/2005/150/made/data.pdf", "label": "www.legislation.gov.uk", "score": 10.3230667114, "published": false}, {"hash": "fjMbjEF3Dne", "uri": "https://www.legislation.gov.uk/en/nisr/2005/150/made/data.pdf", "label": "www.legislation.gov.uk", "score": 10.1026697159, "published": false}, {"hash": "c8zc3s7OXYm", "uri": "http://www.legislation.gov.uk/nisr/2005/150/made/data.xht", "label": "www.legislation.gov.uk", "score": 8.1704311371, "published": false}], "snippet": "means the person of the opposite sex to the claimant in relation to whom the claimant claims that his work is of equal value as described in section 1(2)(c) of the Equal Pay Act(28);", "snippet_links": [{"key": "the-claimant", "type": "clause", "offset": [40, 52]}, {"key": "in-relation-to", "type": "clause", "offset": [53, 67]}, {"key": "equal-pay", "type": "clause", "offset": [164, 173]}], "hash": "551f563a18e4724c1c1bca5f5c56804a", "id": 1}, {"size": 5, "samples": [{"hash": "9BDH545FmS9", "uri": "/contracts/9BDH545FmS9#comparator", "label": "Framework Agreement", "score": 23.0205345154, "published": true}, {"hash": "1lTSinPAIgi", "uri": "/contracts/1lTSinPAIgi#comparator", "label": "Framework Agreement", "score": 23.0205345154, "published": true}, {"hash": "kx3qrd4QR9a", "uri": "/contracts/kx3qrd4QR9a#comparator", "label": "Framework Agreement", "score": 22.9247093201, "published": true}], "snippet": "\u201cComparator Information\u201d \u201cComparator means the information notified by the Supplier to the Customer from time to time in writing (if any) comprising information of a commercially sensitive nature relating to the Supplier, its IPR or its business or which the Supplier has indicated to the Customer that, if disclosed by the Customer, would cause the Supplier significant commercial disadvantage or material financial loss, provided that any such information which is Contract Information provided to OGC pursuant to clause 8 shall not be treated as commercially sensitive; means an individual who is a permanent employee of the Customer engaged in the same or broadly similar work having regard, where relevant, to whether they have a similar level of qualifications or skills and are based at the same location and within the same Customer department; means the information on the Customer\u2019s employees basic pay, overtime payments, shift and unsocial allowance payments, payments for and including annual leave; means the rate of pay comparable to the Customer\u2019s Comparator\u2019s employee rate of pay which will be paid Rate\u201d to the Contractor if and when s/he completes the Qualifying Period. Such rate will include [hourly rate]/[basic pay] (if applicable), bonus payments (if applicable), commission (if applicable), overtime payments, holiday pay or other emoluments subject to any deductions as required by Law;", "snippet_links": [{"key": "comparator-information", "type": "definition", "offset": [1, 23]}, {"key": "the-information", "type": "clause", "offset": [43, 58]}, {"key": "from-time-to-time", "type": "clause", "offset": [100, 117]}, {"key": "in-writing", "type": "definition", "offset": [118, 128]}, {"key": "information-of-a", "type": "clause", "offset": [149, 165]}, {"key": "commercially-sensitive", "type": "definition", "offset": [166, 188]}, {"key": "to-the-supplier", "type": "clause", "offset": [205, 220]}, {"key": "by-the-customer", "type": "clause", "offset": [317, 332]}, {"key": "financial-loss", "type": "clause", "offset": [407, 421]}, {"key": "provided-that", "type": "definition", "offset": [423, 436]}, {"key": "information-which", "type": "clause", "offset": [446, 463]}, {"key": "information-provided", "type": "clause", "offset": [476, 496]}, {"key": "clause-8", "type": "clause", "offset": [516, 524]}, {"key": "an-individual", "type": "clause", "offset": [579, 592]}, {"key": "employee-of-the-customer", "type": "definition", "offset": [612, 636]}, {"key": "engaged-in", "type": "definition", "offset": [637, 647]}, {"key": "similar-work", "type": "definition", "offset": [668, 680]}, {"key": "where-relevant", "type": "clause", "offset": [696, 710]}, {"key": "same-location", "type": "definition", "offset": [798, 811]}, {"key": "information-on", "type": "clause", "offset": [863, 877]}, {"key": "basic-pay", "type": "clause", "offset": [903, 912]}, {"key": "overtime-payments", "type": "clause", "offset": [914, 931]}, {"key": "allowance-payments", "type": "clause", "offset": [952, 970]}, {"key": "payments-for", "type": "clause", "offset": [972, 984]}, {"key": "annual-leave", "type": "clause", "offset": [999, 1011]}, {"key": "the-rate", "type": "definition", "offset": [1019, 1027]}, {"key": "employee-rate-of-pay", "type": "clause", "offset": [1077, 1097]}, {"key": "to-the-contractor", "type": "clause", "offset": [1123, 1140]}, {"key": "qualifying-period", "type": "clause", "offset": [1172, 1189]}, {"key": "if-applicable", "type": "definition", "offset": [1241, 1254]}, {"key": "bonus-payments", "type": "definition", "offset": [1257, 1271]}, {"key": "holiday-pay", "type": "definition", "offset": [1336, 1347]}, {"key": "subject-to", "type": "definition", "offset": [1368, 1378]}, {"key": "as-required-by-law", "type": "clause", "offset": [1394, 1412]}], "hash": "6121a1d3ba8952ed3c9eed462e483110", "id": 2}, {"size": 4, "samples": [{"hash": "v511lD12o1", "uri": "/contracts/v511lD12o1#comparator", "label": "Master Services Agreement (Aspen Insurance Holdings LTD)", "score": 35.9431877136, "published": true}, {"hash": "4JeqtSCUlgm", "uri": "/contracts/4JeqtSCUlgm#comparator", "label": "Master Services Agreement (Aspen Insurance Holdings LTD)", "score": 35.2587280273, "published": true}, {"hash": "i2Pg7KUMV8Z", "uri": "/contracts/i2Pg7KUMV8Z#comparator", "label": "Master Services Agreement (Aspen Insurance Holdings LTD)", "score": 34.9657783508, "published": true}], "snippet": "has the meaning given to it in Schedule 9;", "snippet_links": [{"key": "schedule-9", "type": "definition", "offset": [31, 41]}], "hash": "0d12e5a64edc7e66966960dd2df224f0", "id": 3}, {"size": 4, "samples": [{"hash": "hDxNYjwUbCO", "uri": "https://www.legislation.gov.uk/uksi/2013/1237/2016-11-28/data.pdf", "label": "www.legislation.gov.uk", "score": 10.8904857635, "published": false}, {"hash": "bazBKdSCa7E", "uri": "https://www.legislation.gov.uk/uksi/2013/1237/data.pdf", "label": "www.legislation.gov.uk", "score": 10.8658456802, "published": false}, {"hash": "5P7PyT49QGs", "uri": "https://www.legislation.gov.uk/uksi/2013/1237/made/data.pdf", "label": "www.legislation.gov.uk", "score": 10.8644762039, "published": false}], "snippet": "means the person of the opposite sex to the claimant in relation to whom the claimant alleges that his or her work is of equal value;", "snippet_links": [{"key": "the-claimant", "type": "clause", "offset": [40, 52]}, {"key": "in-relation-to", "type": "clause", "offset": [53, 67]}], "hash": "4f89cd7524407a330a12e57f49fe0b4a", "id": 4}, {"size": 4, "samples": [{"hash": "7iOsDmb3q4L", "uri": "/contracts/7iOsDmb3q4L#comparator", "label": "Framework Agreement", "score": 21.8624229431, "published": true}, {"hash": "3z5lbVeBss1", "uri": "/contracts/3z5lbVeBss1#comparator", "label": "Framework Agreement", "score": 19.5578365326, "published": true}, {"hash": "jV5eZEPdPFT", "uri": "/contracts/jV5eZEPdPFT#comparator", "label": "Framework Agreement", "score": 19.4236831665, "published": true}], "snippet": "has the same meaning as it is given in Regulation 5 of the AWR;", "snippet_links": [{"key": "same-meaning", "type": "clause", "offset": [8, 20]}, {"key": "regulation-5", "type": "definition", "offset": [39, 51]}], "hash": "ec02c46f25fe97480ab0dd9658265a05", "id": 5}, {"size": 4, "samples": [{"hash": "6IU5Cw3WSme", "uri": "/contracts/6IU5Cw3WSme#comparator", "label": "License Agreement (Genmab a/S)", "score": 30.4017791748, "published": true}, {"hash": "5wyUW5t7308", "uri": "/contracts/5wyUW5t7308#comparator", "label": "License Agreement (Genmab a/S)", "score": 30.2484607697, "published": true}, {"hash": "jq0JsHxEhhY", "uri": "/contracts/jq0JsHxEhhY#comparator", "label": "Co Development and Collaboration Agreement (Genmab a/S)", "score": 29.4017791748, "published": true}], "snippet": "means an investigational or marketed drug used as a reference in a Clinical Study.", "snippet_links": [{"key": "as-a-reference", "type": "definition", "offset": [47, 61]}, {"key": "clinical-study", "type": "definition", "offset": [67, 81]}], "hash": "059774e621c53d22451453312018a600", "id": 6}, {"size": 3, "samples": [{"hash": "gpQEYj0xKsp", "uri": "/contracts/gpQEYj0xKsp#comparator", "label": "Wep Strategic Partnering Agreement", "score": 31.6921577454, "published": true}, {"hash": "iEZp5dOJIXx", "uri": "/contracts/iEZp5dOJIXx#comparator", "label": "Wep Strategic Partnering Agreement", "score": 31.6839466095, "published": true}, {"hash": "6JtOLWh12WO", "uri": "/contracts/6JtOLWh12WO#comparator", "label": "Wep Strategic Partnering Agreement", "score": 26.2553043365, "published": true}], "snippet": "means the relevant element(s) and/or component(s) of the relevant project(s) from the Pricing Data which are: (a) agreed between WEPCo and the Relevant Participants pursuant to paragraphs 2.2.11 and 2.3 of Schedule 5 (Approval Process for New Projects) or determined by the SPB pursuant to paragraph 2.4 of Schedule 5 (Approval Process for New Projects) for the purpose of determining any revised Project Development Fee Cap for a New Project; and/or (b) agreed between WEPCo and the Relevant Participants pursuant to paragraph 3.1.1 of Schedule 6 (New Project Pricing Report) for the purposes of determining the appropriate cap for stages of New Projects to apply pursuant to paragraph 3.2 of Schedule 6 (New Project Pricing Report); it being recognised that the Comparators for specific elements or components of a New Project may be from different projects within the Pricing Data;", "snippet_links": [{"key": "the-relevant", "type": "clause", "offset": [6, 18]}, {"key": "pricing-data", "type": "definition", "offset": [86, 98]}, {"key": "schedule-5", "type": "definition", "offset": [206, 216]}, {"key": "approval-process", "type": "definition", "offset": [218, 234]}, {"key": "new-projects", "type": "clause", "offset": [239, 251]}, {"key": "pursuant-to-paragraph", "type": "clause", "offset": [278, 299]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [354, 372]}, {"key": "project-development-fee-cap", "type": "definition", "offset": [397, 424]}, {"key": "schedule-6", "type": "clause", "offset": [537, 547]}, {"key": "pricing-report", "type": "definition", "offset": [561, 575]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [577, 596]}, {"key": "to-apply", "type": "clause", "offset": [656, 664]}], "hash": "b0522e03718eeea612ad78ec50990e7b", "id": 7}, {"size": 3, "samples": [{"hash": "O1eRzTkrun", "uri": "/contracts/O1eRzTkrun#comparator", "label": "Umbrella Development Services Agreement", "score": 31.3408622742, "published": true}, {"hash": "fKVS85lwX17", "uri": "/contracts/fKVS85lwX17#comparator", "label": "Umbrella Development Services Agreement (Kaleido Biosciences, Inc.)", "score": 30.1334705353, "published": true}, {"hash": "65umv2bAI9F", "uri": "/contracts/65umv2bAI9F#comparator", "label": "Umbrella Development Services Agreement (Kaleido Biosciences, Inc.)", "score": 29.8158798218, "published": true}], "snippet": "means a commercially available investigational or marketed drug product.", "snippet_links": [{"key": "commercially-available", "type": "definition", "offset": [8, 30]}, {"key": "drug-product", "type": "definition", "offset": [59, 71]}], "hash": "7343a132dae53a8662cdd3d3232108ac", "id": 8}, {"size": 2, "samples": [{"hash": "dfLIbk7JeRW", "uri": "/contracts/dfLIbk7JeRW#comparator", "label": "Wep Strategic Partnering Agreement", "score": 31.5580272675, "published": true}, {"hash": "kOlydZKzB70", "uri": "/contracts/kOlydZKzB70#comparator", "label": "Wep Strategic Partnering Agreement", "score": 26.4770698547, "published": true}], "snippet": "means the relevant element(s) and/or component(s) of the relevant project(s) from the Pricing Data which are:", "snippet_links": [{"key": "the-relevant", "type": "clause", "offset": [6, 18]}, {"key": "pricing-data", "type": "definition", "offset": [86, 98]}], "hash": "8673321ec7a0a3d4dba0c133fb236b23", "id": 9}, {"size": 2, "samples": [{"hash": "3zulqnDn5FM", "uri": "https://doc.morningstar.com/document/7afeaea0504bf0bb2e480f9f3839793e.msdoc/?clientid=euretailsite&key=9ab7c1c01e51bcec", "label": "doc.morningstar.com", "score": 11.6794900894, "published": false}, {"hash": "fO5jpF4CQHm", "uri": "https://tbaileyam.co.uk/wp-content/uploads/2020/01/19-12-16-T.-Bailey-Funds-Prospectus.pdf", "label": "tbaileyam.co.uk", "score": 5.973306179, "published": false}], "snippet": "means a factor against which investors may compare a Scheme\u2019s performance; \u201cFSA\u201d means the Financial Services Authority, the predecessor to the Financial Conduct Authority; \u201cPRN\u201d means the FCA Product Reference Number of the relevant Scheme; \u201cRolling Period\u201d means a defined period of time going back from a given date, where the given date moves forward by 1 day every day; \u201cTarget\u201d refers to a level of performance which the Investment Manager has in mind when managing a Scheme and is usually expressed by reference to an index or as a particular value. There is no certainty that the target will be achieved and it is notguaranteed;", "snippet_links": [{"key": "financial-services-authority", "type": "definition", "offset": [91, 119]}, {"key": "the-financial-conduct-authority", "type": "clause", "offset": [140, 171]}, {"key": "number-of", "type": "definition", "offset": [211, 220]}, {"key": "the-relevant", "type": "clause", "offset": [221, 233]}, {"key": "rolling-period", "type": "clause", "offset": [243, 257]}, {"key": "period-of-time", "type": "clause", "offset": [275, 289]}, {"key": "every-day", "type": "clause", "offset": [364, 373]}, {"key": "level-of-performance", "type": "definition", "offset": [396, 416]}, {"key": "the-investment-manager", "type": "definition", "offset": [423, 445]}, {"key": "reference-to", "type": "clause", "offset": [509, 521]}, {"key": "the-target", "type": "clause", "offset": [584, 594]}], "hash": "fcf8f47dc22c865859b2464b18a764a7", "id": 10}], "next_curs": "ClcSUWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjMLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiITY29tcGFyYXRvciMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 53, "snippet": "means the person of the opposite sex to the claimant in relation to whom the claimant claims that his work is of equal value as described in section 1(2)(c) of the Equal Pay Act(28);", "title": "Comparator", "id": "comparator", "examples": ["Any other use of Sponsor Drug or <strong>Comparator</strong> Drug constitutes a material breach of this Agreement.", "Institution and Principal Investigator will use Sponsor Drug or <strong>Comparator</strong> Drug only as specified in the Protocol.", "Institution will return and/or destroy any unused Sponsor Drug or <strong>Comparator</strong> Drug, as applicable, at Sponsor\u2019s expense.", "Institution and Principal Investigator will adhere to Applicable Law requiring careful custody and dispensing of Sponsor Drug or <strong>Comparator</strong> Drug, as well as appropriate documentation of such activities.", "Institution and Principal Investigator will not charge a Trial Subject or third-party payer for Sponsor Drug or <strong>Comparator</strong> Drug or for any services reimbursed by Sponsor or its designee under this Agreement.", "Institution and Principal Investigator will maintain appropriate control of supplies of Sponsor Drug or <strong>Comparator</strong> Drug and will not administer or dispense it to anyone who is not a Trial Subject, or provide access to it to anyone except Research Staff.", "Neither the Institution nor the Principal Investigator will directly or indirectly seek or receive compensation from Trial Subjects or third-party payers for any material, treatment or service that is required by the Protocol and provided or paid by Sponsor or its designee, including, but not limited to, Sponsor Drug, <strong>Comparator</strong> Drug, Trial Subject screening, infusions, physician and nurse services, diagnostic tests, and Sponsor Drug and/or <strong>Comparator</strong> Drug administration.", "After the Final Year of the Performance Period, the results of each company in the <strong>Comparator</strong> Peer Group will be arrayed from highest to lowest.", "The \u201cTSR Performance Multiplier\u201d will be determined by comparing the Company\u2019s total stockholder return to the total stockholder return of each of the companies in the <strong>Comparator</strong> Peer Group (as set forth below) over the period commencing on the Award Date and ending on the third anniversary of the Award Date (the \u201cPerformance Period\u201d) to determine the Company\u2019s TSR ranking against the <strong>Comparator</strong> Group.", "The percentile ranking of the Company\u2019s Relative Total Stockholder Return shall be that fraction which is calculated by dividing the number of companies in the <strong>Comparator</strong> Group whose <strong>Comparator</strong> Total Stockholder Return performance is exceeded by the Company (based on the Total Stockholder Return) by the total number of companies in the <strong>Comparator</strong> Group."], "related": [["comparator-group", "Comparator Group", "<strong>Comparator</strong> Group"], ["comparative-price", "comparative price", "comparative price"], ["weighting", "Weighting", "Weighting"], ["autocycle", "Autocycle", "Autocycle"], ["product-group", "Product Group", "Product Group"]], "related_snippets": [], "updated": "2025-07-17T06:20:50+00:00"}, "json": true, "cursor": ""}}